| Prophylaxis Vaccine Antibodies Ebola (NCT04822376) | ANRS, Emerging Infectious Diseases | 2021-10-17 |
| Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) (NCT05064956) | London School of Hygiene and Tropical Medicine | 2021-10-06 |
| INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees (NCT04906629) | University of Geneva, Switzerland | 2021-09-01 |
| Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study) (NCT04711356) | London School of Hygiene and Tropical Medicine | 2021-07-08 |
| Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (NCT05130398) | Centre de Recherche Médicale de Lambaréné | 2021-04-09 |
| An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease (NCT04717830) | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 2021-02-15 |
| Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC (NCT04235361) | University of Stirling | 2021-01-15 |
| Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults (NCT04723602) | Albert B. Sabin Vaccine Institute | 2021-01-06 |
| Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola) (NCT04409405) | Institut National de la Santé Et de la Recherche Médicale, France | 2020-04-16 |
| Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola (NCT04186000) | Universiteit Antwerpen | 2019-12-18 |
| Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response (NCT04250168) | Institute of Tropical Medicine, Belgium | 2019-11-11 |
| A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants (NCT03929757) | Janssen Vaccines & Prevention B.V. | 2019-08-19 |
| ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo) (NCT04028349) | MRC/UVRI and LSHTM Uganda Research Unit | 2019-08-01 |
| EBOVAC-Salone Extension (NCT03820739) | London School of Hygiene and Tropical Medicine | 2019-07-22 |
| Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease (NCT04815174) | Alliance for International Medical Action | 2018-08-01 |
| Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein (NCT03462004) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-03-05 |
| Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up (NCT02431923) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-02 |
| PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response (NCT03098862) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-04 |
| International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi (NCT03072030) | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 2017-08-03 |
| Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines (NCT03140774) | University of Oxford | 2017-05-17 |
| Partnership for Research on Ebola VACcinations (NCT02876328) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-27 |
| Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults (NCT02718469) | Auro Vaccines LLC | 2015-12-22 |
| Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo (NCT02509494) | Janssen Vaccines & Prevention B.V. | 2015-09-30 |
| A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV (NCT02495246) | University of Oxford | 2015-09-21 |
| A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization (NCT02533791) | Jiangsu Province Centers for Disease Control and Prevention | 2015-07-01 |
| Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination (NCT02485912) | University of Oxford | 2015-07-01 |
| A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z (NCT02451891) | University of Oxford | 2015-05-06 |
| Multiple Treatments for Ebola Virus Disease (EVD) (NCT02380625) | Clinical Research Management, Inc. | 2015-04-01 |
| A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. (NCT02401373) | First Affiliated Hospital of Zhejiang University | 2015-03-01 |
| Evaluation of the FilmArray BioThreat-E Test (NCT02658331) | BioMérieux | 2015-03-01 |
| Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO) (NCT02368119) | University of Maryland, Baltimore | 2015-03-01 |
| Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) (NCT02307591) | Emergency NGO Onlus | 2014-12-01 |
| A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. (NCT02296983) | University of Oxford | 2014-12-01 |
| A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. (NCT02326194) | Jiangsu Province Centers for Disease Control and Prevention | 2014-12-01 |
| Efficacy of Favipiravir Against Ebola (JIKI) (NCT02329054) | Institut National de la Santé Et de la Recherche Médicale, France | 2014-12-01 |
| Efficacy of Favipiravir Against Severe Ebola Virus Disease (NCT02662855) | Beijing Institute of Pharmacology and Toxicology | 2014-11-01 |
| Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment (NCT02333578) | Clinical Research Management, Inc. | 2014-11-01 |
| Phase 1 Trial of Ebola Vaccine in Mali (NCT02267109) | University of Maryland, Baltimore | 2014-10-01 |
| An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola (NCT04268966) | Jazz Pharmaceuticals | 2014-10-01 |
| Evaluating an Ebola and a Marburg Vaccine in Uganda (NCT00997607) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-02-01 |
| Ebola and Marburg Virus Vaccines (NCT00605514) | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-01-25 |
| Experimental Vaccine for Prevention of Ebola Virus Infection (NCT00374309) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-09-05 |
| Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP (NCT05067166) | Ridgeback Biotherapeutics, LP | |
| R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease (NCT03576690) | Regeneron Pharmaceuticals | |